Navigation Links
Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
Date:10/30/2007

SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that Adrian Adams has been elected to the company's Board of Directors effective immediately.

"We are very pleased to welcome Adrian to the Amylin Board," said Daniel M. Bradbury, President and CEO of Amylin Pharmaceuticals. "His international experience as a highly innovative, strategic business leader, combined with a track record of building organizations and delivering optimum results will enhance our Board's depth of experience."

Mr. Adams currently serves as President and CEO of Sepracor, Inc. Prior to this he was President and Chief Executive Officer of Kos Pharmaceuticals from 2002 until the acquisition of the company by Abbott Laboratories in December 2006. Mr. Adams has over 30 years of experience in both specialty and large pharmaceutical organizations that, in addition to Sepracor and Kos, included careers with ICI, SmithKline Beecham and Novartis, and involved work and product launches in most therapeutic areas. Mr. Adams has a broad background encompassing research and development, sales, international and national product marketing, business development and extensive general management experience.

He is a graduate of Manchester University in the United Kingdom with a Bachelor of Science degree.

In addition to serving on the Amylin Board, Mr. Adams is actively involved as a board member of PhRMA (Pharmaceutical Research and Manufacturer of America).

About Amylin

Amylin Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 1,800 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Group promoting classified research elects officers
4. Miller Brewing selects Procuri software
5. Uniden selects Catalyst RFID software
6. Hammes Co. selects SiteStuff as procurement company
7. Meat-snack maker selects Prescient Applied Intelligence tech package
8. UW Colleges selects Allot Communications to manage multi-campus network
9. ProHealth Care selects NetScaler delivery system
10. Merkle selects Firstlogic data quality software
11. We Energies selects Frictionless SRM Software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):